ZBH - חוב כולל להון Zimmer Biomet Holdings

Zimmer Biomet Holdings (ZBH) possesses significant pricing power, although healthcare budgets limit price growth. The current total debt-to-equity ratio allows for an assessment of financial stability, and 0.56 captures the current value of this indicator. Revenues are based on the sale of robotics and joint implants. The market is divided among tech giants, where physician commitment to specific tools guarantees long-term vendor loyalty.

The total debt-to-equity ratio measures the proportion of borrowed funds within the asset financing structure. This coefficient determines the company's dependence on external creditors and its solvency. By analyzing the leverage level relative to the equity of Zimmer Biomet Holdings (ZBH), an investor assesses the business's margin of safety. Amid geopolitical risks and medtech supply chain disruptions, excessive debt may limit the company's adaptability. A stable metric confirms the model's resilience to external shocks.